The present data show a relevant astrocyte involvement in the positive impact obtained by the mGluR5 genetic downregulation in ALS mice, thus strongly supporting the hypothesis that selective approaches aimed at targeting a specific cell population may represent an intriguing therapeutic strategy. The gene discussed is GRM5; the disease is amyotrophic lateral sclerosis.